Close

Medicinova (MNOV) Receives Nortice of Allowance from EPO for MN-029 Patent

Go back to Medicinova (MNOV) Receives Nortice of Allowance from EPO for MN-029 Patent

MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in Europe

January 13, 2016 6:00 PM EST

LA JOLLA, Calif., Jan. 13, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced receipt from the European Patent Office of a notice of intent to allow patent for MN-029 (denibulin) di-hydrochloride.

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2032.  The allowed claims cover the compound, pharmaceutical compositions and a method of treating certain cell proliferative diseases, including cancer, using MN-029 (denibulin) di-hydrochloride. ... More